Newsroom

LATEST PUBLICATIONS

Measurable Residual Disease detection in acute lymphoblastic leukaemia – comparison between targeted NGS and ASO-qPCR

2026-07-09T17:00:41-07:00January 23rd, 2026|

Measurable residual disease monitoring after hematopoietic stem cell transplantation

2026-07-06T16:26:02-07:00December 30th, 2025|

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

2025-11-24T09:51:38-08:00November 24th, 2025|

QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3–Internal Tandem Duplications for Treatment With Quizartinib

2026-04-20T09:03:35-07:00September 3rd, 2025|

A Systematic, Evidence-Based Workflow for Classifying KMT2A Fusions in AML

2026-04-20T09:01:54-07:00July 29th, 2025|

Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay

2026-03-09T18:44:44-07:00April 22nd, 2025|

Invivoscribe Announces Registration of the LeukoStrat^® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland

2026-03-09T18:48:48-07:00March 27th, 2025|

EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA

2024-10-08T03:14:44-07:00October 8th, 2024|

Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML

2026-03-09T18:43:04-07:00May 8th, 2024|

Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA

2025-08-26T07:35:25-07:00July 21st, 2023|

16th JSH International Symposium

May 15 – 16, 2026
Kamakura, Japan
Attending

ASCO

May 29-Jun 3, 2026
Chicago, IL
Exhibiting
Meet with our team at ASCO

Festival of Genomics, Biodata & AI

Jun 3-4, 2026
Boston, MA
Exhibiting
Meet our team

The 66th Annual Meeting of the Japanese Society of Lymphoma Research

Jun 4 – 6, 2026
Tokyo, Japan
Attending

EHA

Jun 11-14, 2026
Stockholm, Sweden
Exhibiting
Meet with our team at EHA

Newsroom

Newsroom

LATEST PUBLICATIONS

Measurable Residual Disease detection in acute lymphoblastic leukaemia – comparison between targeted NGS and ASO-qPCR

Measurable residual disease monitoring after hematopoietic stem cell transplantation

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3–Internal Tandem Duplications for Treatment With Quizartinib

A Systematic, Evidence-Based Workflow for Classifying KMT2A Fusions in AML

LATEST PRESS

Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay

Invivoscribe Announces Registration of the LeukoStrat^® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland

EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA

Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML

Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA

CONFERENCES

16th JSH International Symposium

ASCO

Festival of Genomics, Biodata & AI

The 66th Annual Meeting of the Japanese Society of Lymphoma Research

EHA

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶